You are here

Vaccines Pipeline

Pfizer's mission is to deliver medicines that make a real difference in quality of life for patients with vaccines-related conditions. Scientists in our research and development (R&D) programs are committed to speeding the delivery of new treatments. We pledge to maintain the safety of patients who take part in our trials and to uphold the highest ethical standards in all of our research initiatives.

On this page, you will find more information about our pipeline, which investigational therapies are under development, and in which stages.

 

Vaccines Pipeline as of

  • Discovery Projects
  • Phase 1
    4
  • Phase 2
    1
  • Phase 3
    1
  • Registration
    0
  • Total6
 
Compound Name
Indication
Phasesort descending
Submission Type
Compound Type
PF-06482077
Therapeutic Area:
Vaccines
Phase:Phase 1
Compound Type:Vaccine
Business Segment:
WRD
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Invasive and non-invasive Pneumococcal infections Phase 1 New Molecular Entity Vaccine
PF-06753512
Therapeutic Area:
Vaccines
Phase:Phase 1
Compound Type:Vaccine
Business Segment:
WRD
Mechanism of Action:
Therapeutic Vaccine
Go to clinical trial
Prostate Cancer Phase 1 New Molecular Entity Vaccine
PF-06760805
Therapeutic Area:
Vaccines
Phase:Phase 1
Compound Type:Vaccine
Business Segment:
WRD
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Invasive Group B streptococcus infection
Project advanced
Phase 1 New Molecular Entity Vaccine
PF-06886992
Therapeutic Area:
Vaccines
Phase:Phase 1
Compound Type:Vaccine
Business Segment:
WRD
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Serogroups ABCWY meningococcal infections
Project advanced
Phase 1 New Molecular Entity Vaccine
PF-06290510
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Invasive Staphylococcus aureus infections in surgical populations (FAST TRACK) Phase 2 New Molecular Entity Vaccine
PF-06425090
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRD
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Primary clostridium difficile infection (FAST TRACK) Phase 3 New Molecular Entity Vaccine